Preoperative irradiation for the prevention of heterotopic ossification induces local inflammation in humans

Bone

Volumn 55, Issue 1, 2013, Pages 93-101

  Hoff, Paula ^a,b   Rakow, Anastasia ^a   Gaber, Timo ^a,b,c   Hahne, Martin ^a,b,d   Sentürk, Ufuk ^a   Strehl, Cindy ^a,b   Fangradt, Monique ^a,b   Schmidt Bleek, Katharina ^e   Huscher, Dörte ^a,b   Winkler, Tobias ^a   Matziolis, Dörte ^a   Matziolis, Georg ^a,c   Badakhshi, Harun ^a   Burmester, Gerd Rüdiger ^a   Duda, Georg N ^a,e   Perka, Carsten ^a,c   Buttgereit, Frank ^a,b,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^c Berlin Brandenburg Center for Regenerative Therapies   (Germany)

^d Berlin Brandenburg School for Regenerative Therapies   (Germany)

^e Julius Wolff Institut   (Germany)

Author keywords

Cytokines; Heterotopic ossification; Immune cells; Inflammation; Total hip arthroplasty

Indexed keywords

CD45RA ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; RANTES; VASCULOTROPIN;

ARTICLE; CELL COMPOSITION; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; FEMUR; HEMATOMA; HETEROTOPIC OSSIFICATION; HIP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; INFLAMMATION; NATURAL KILLER CELL; POSTOPERATIVE CARE; PREOPERATIVE RADIOTHERAPY; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHROPLASTY, REPLACEMENT, HIP; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINES; FLOW CYTOMETRY; HEMATOMA; HIP; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MODELS, BIOLOGICAL; NATURAL KILLER T-CELLS; OSSIFICATION, HETEROTOPIC; POSTOPERATIVE CARE; PREOPERATIVE CARE; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84877039859     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.03.020     Document Type: Article

References (68)

1. McCarthy E.F., Sundaram M. Heterotopic ossification: a review. Skeletal Radiol 2005, 34:609-619.
2. Balboni T.A., Gobezie R., Mamon H.J. Heterotopic ossification: pathophysiology, clinical features, and the role of radiotherapy for prophylaxis. Int J Radiat Oncol Biol Phys 2006, 65:1289-1299.
3. Freeman T.A., Parvizi J., Dela Valle C.J., Steinbeck M.J. Mast cells and hypoxia drive tissue metaplasia and heterotopic ossification in idiopathic arthrofibrosis after total knee arthroplasty. Fibrogenesis Tissue Repair 2010, 3:17.
4. Gannon F.H., Glaser D., Caron R., Thompson L.D., Shore E.M., Kaplan F.S. Mast cell involvement in fibrodysplasia ossificans progressiva. Hum Pathol 2001, 32:842-848.
5. Furuya H., Ikezoe K., Wang L., Ohyagi Y., Motomura K., Fujii N., et al. A unique case of fibrodysplasia ossificans progressiva with an ACVR1 mutation, G356D, other than the common mutation (R206H). Am J Med Genet A 2008, 146A:459-463.
6. Shore E.M., Xu M., Feldman G.J., Fenstermacher D.A., Cho T.J., Choi I.H., et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 2006, 38:525-527.
7. Kan L., Liu Y., McGuire T.L., Berger D.M., Awatramani R.B., Dymecki S.M., et al. Dysregulation of local stem/progenitor cells as a common cellular mechanism for heterotopic ossification. Stem Cells 2009, 27:150-156.
8. Kaplan F.S., Xu M., Seemann P., Connor J.M., Glaser D.L., Carroll L., et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat 2009, 30:379-390.
9. Scarlett R.F., Rocke D.M., Kantanie S., Patel J.B., Shore E.M., Kaplan F.S. Influenza-like viral illnesses and flare-ups of fibrodysplasia ossificans progressiva. Clin Orthop Relat Res 2004, 275-279.
10. Vavken P., Castellani L., Sculco T.P. Prophylaxis of heterotopic ossification of the hip: systematic review and meta-analysis. Clin Orthop Relat Res 2009, 467:3283-3289.
11. Grohs J.G., Schmidt M., Wanivenhaus A. Selective COX-2 inhibitor versus indomethacin for the prevention of heterotopic ossification after hip replacement: a double-blind randomized trial of 100 patients with 1-year follow-up. Acta Orthop 2007, 78:95-98.
12. Rapuano B.E., Boursiquot R., Tomin E., Macdonald D.E., Maddula S., Raghavan D., et al. The effects of COX-1 and COX-2 inhibitors on prostaglandin synthesis and the formation of heterotopic bone in a rat model. Arch Orthop Trauma Surg 2008, 128:333-344.
13. Kolar P., Lach S., Gaber T., Maschmeyer P., Dziurla R., Tripmacher R., et al. Effects of celecoxib on the expression of osteoprotegerin, energy metabolism and cell viability in cultured human osteoblastic cells. Clin Exp Rheumatol 2009, 27:99-107.
14. Zhang X., Schwarz E.M., Young D.A., Puzas J.E., Rosier R.N., O'Keefe R.J. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 2002, 109:1405-1415.
15. Gerstenfeld L.C., Thiede M., Seibert K., Mielke C., Phippard D., Svagr B., et al. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs. J Orthop Res 2003, 21:670-675.
16. Burd T.A., Hughes M.S., Anglen J.O. Heterotopic ossification prophylaxis with indomethacin increases the risk of long-bone nonunion. J Bone Joint Surg Br 2003, 85:700-705.
17. Ham A. A histological study of the early phases of bone repair. J Bone Joint Surg Am 1930, 827-844.
18. McKibbin B. The biology of fracture healing in long bones. J Bone Joint Surg Br 1978, 60-B:150-162.
19. Kolar P., Schmidt-Bleek K., Schell H., Gaber T., Toben D., Schmidmaier G., et al. The early fracture hematoma and its potential role in fracture healing. Tissue Eng Part B Rev 2010, 16:427-434.
20. Fransen M., Neal B. Non-steroidal anti-inflammatory drugs for preventing heterotopic bone formation after hip arthroplasty. Cochrane Database Syst Rev 2004, CD001160.
21. Kienapfel H., Koller M., Wust A., Sprey C., Merte H., Engenhart-Cabillic R., et al. Prevention of heterotopic bone formation after total hip arthroplasty: a prospective randomised study comparing postoperative radiation therapy with indomethacin medication. Arch Orthop Trauma Surg 1999, 119:296-302.
22. Rosendahl S., Christoffersen J.K., Norgaard M. Para-articular ossification following hip replacement. 70 arthroplasties ad modum Moore using McFarland's approach. Acta Orthop Scand 1977, 48:400-404.
23. Donneys A., Weiss D.M., Deshpande S.S., Ahsan S., Tchanque-Fossuo C.N., Sarhaddi D., et al. Localized deferoxamine injection augments vascularity and improves bony union in pathologic fracture healing after radiotherapy. Bone 2013, 52:318-325.
24. Simon L.S., Smolen J.S., Abramson S.B., Appel G., Bombardier C., Brater D.C., et al. Controversies in COX-2 selective inhibition. J Rheumatol 2002, 29:1501-1510.
25. Charbord P. Bone marrow mesenchymal stem cells: historical overview and concepts. Hum Gene Ther 2010, 21:1045-1056.
26. Pellegrini V.D., Gregoritch S.J. Preoperative irradiation for prevention of heterotopic ossification following total hip arthroplasty. J Bone Joint Surg Am 1996, 78:870-881.
27. Pavlou G., Salhab M., Murugesan L., Jallad S., Petsatodis G., West R., et al. Risk factors for heterotopic ossification in primary total hip arthroplasty. Hip Int 2012, 22:50-55.
28. Agematsu K. Memory B, cells and CD27. Histol Histopathol 2000, 15:573-576.
29. Kim K.M., Reth M. Signaling difference between class IgM and IgD antigen receptors. Ann N Y Acad Sci 1995, 766:81-88.
30. Lampropoulou V., Calderon-Gomez E., Roch T., Neves P., Shen P., Stervbo U., et al. Suppressive functions of activated B cells in autoimmune diseases reveal the dual roles of Toll-like receptors in immunity. Immunol Rev 2010, 233:146-161.
31. Ishikawa H., Tanaka K., Kutsukake E., Fukui T., Sasaki H., Hata A., et al. IFN-gamma production downstream of NKT cell activation in mice infected with influenza virus enhances the cytolytic activities of both NK cells and viral antigen-specific CD8+ T cells. Virology 2010, 407:325-332.
32. Moreno M., Molling J.W., von Mensdorff-Pouilly S., Verheijen R.H., Hooijberg E., Kramer D., et al. IFN-gamma-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses. J Immunol 2008, 181:2446-2454.
33. Wu Z., Xu Y. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation. J Mol Cell Biol 2010, 2:217-222.
34. Park J.E., Barbul A. Understanding the role of immune regulation in wound healing. Am J Surg 2004, 187:11S-16S.
35. Schaffer M., Barbul A. Lymphocyte function in wound healing and following injury. Br J Surg 1998, 85:444-460.
36. Barbul A., Breslin R.J., Woodyard J.P., Wasserkrug H.L., Efron G. The effect of in vivo T helper and T suppressor lymphocyte depletion on wound healing. Ann Surg 1989, 209:479-483.
37. Toben D., Schroeder I., El Khassawna T., Mehta M., Hoffmann J.E., Frisch J.T., et al. Fracture healing is accelerated in the absence of the adaptive immune system. J Bone Miner Res 2011, 26:113-124.
38. Schmidt-Bleek K., Schell H., Schulz N., Hoff P., Perka C., Buttgereit F., et al. Inflammatory phase of bone healing initiates the regenerative healing cascade. Cell Tissue Res 2012, 347:567-573.
39. Nam D., Mau E., Wang Y., Wright D., Silkstone D., Whetstone H., et al. T-lymphocytes enable osteoblast maturation via IL-17F during the early phase of fracture repair. PLoS One 2012, 7:e40044.
40. Bour-Jordan H., Bluestone J.A. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev 2009, 229:41-66.
41. Kolar P., Knieke K., Hegel J.K., Quandt D., Burmester G.R., Hoff H., et al. CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice. Arthritis Rheum 2009, 60:123-132.
42. Clement L.T. Isoforms of the CD45 common leukocyte antigen family: markers for human T-cell differentiation. J Clin Immunol 1992, 12:1-10.
43. Morimoto C., Schlossman S.F. P. Rambotti Lecture. Human naive and memory T cells revisited: new markers (CD31 and CD27) that help define CD4+ T cell subsets. Clin Exp Rheumatol 1993, 11:241-247.
44. Bromley S.K., Thomas S.Y., Luster A.D. Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics. Nat Immunol 2005, 6:895-901.
45. Facoetti A., Mariotti L., Ballarini F., Bertolotti A., Nano R., Pasi F., et al. Experimental and theoretical analysis of cytokine release for the study of radiation-induced bystander effect. Int J Radiat Biol 2009, 85:690-699.
46. Ivanov V.N., Zhou H., Ghandhi S.A., Karasic T.B., Yaghoubian B., Amundson S.A., et al. Radiation-induced bystander signaling pathways in human fibroblasts: a role for interleukin-33 in the signal transmission. Cell Signal 2010, 22:1076-1087.
47. Mahida Y.R. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis 2000, 6:21-33.
48. Schoenborn J.R., Wilson C.B. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 2007, 96:41-101.
49. Lacotte S., Brun S., Muller S., Dumortier H. CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci 2009, 1173:310-317.
50. Saha B., Jyothi Prasanna S., Chandrasekar B., Nandi D. Gene modulation and immunoregulatory roles of interferon gamma. Cytokine 2010, 50:1-14.
51. Hill N., Sarvetnick N. Cytokines: promoters and dampeners of autoimmunity. Curr Opin Immunol 2002, 14:791-797.
52. Scheffold A., Huhn J., Hofer T. Regulation of CD4+CD25+ regulatory T cell activity: it takes (IL-)two to tango. Eur J Immunol 2005, 35:1336-1341.
53. Boyman O., Letourneau S., Krieg C., Sprent J. Homeostatic proliferation and survival of naive and memory T cells. Eur J Immunol 2009, 39:2088-2094.
54. Allori A.C., Sailon A.M., Warren S.M. Biological basis of bone formation, remodeling, and repair - part I: biochemical signaling molecules. Tissue Eng Part B Rev 2008, 14:259-273.
55. Schipani E., Maes C., Carmeliet G., Semenza G.L. Regulation of osteogenesis-angiogenesis coupling by HIFs and VEGF. J Bone Miner Res 2009, 24:1347-1353.
56. Jacobsen K.A., Al-Aql Z.S., Wan C., Fitch J.L., Stapleton S.N., Mason Z.D., et al. Bone formation during distraction osteogenesis is dependent on both VEGFR1 and VEGFR2 signaling. J Bone Miner Res 2008, 23:596-609.
57. Maes C., Kobayashi T., Selig M.K., Torrekens S., Roth S.I., Mackem S., et al. Osteoblast precursors, but not mature osteoblasts, move into developing and fractured bones along with invading blood vessels. Dev Cell 2010, 19:329-344.
58. Matsubara H., Hogan D.E., Morgan E.F., Mortlock D.P., Einhorn T.A., Gerstenfeld L.C. Vascular tissues are a primary source of BMP2 expression during bone formation induced by distraction osteogenesis. Bone 2012, 51:168-180.
59. Clarkin C.E., Gerstenfeld L.C. VEGF and bone cell signalling: an essential vessel for communication?. Cell Biochem Funct 2013, 31:1-11.
60. Utting J.C., Robins S.P., Brandao-Burch A., Orriss I.R., Behar J., Arnett T.R. Hypoxia inhibits the growth, differentiation and bone-forming capacity of rat osteoblasts. Exp Cell Res 2006, 312:1693-1702.
61. Yadav A., Saini V., Arora S. MCP-1: chemoattractant with a role beyond immunity: a review. Clin Chim Acta 2010, 411:1570-1579.
62. Maurer M., von Stebut E. Macrophage inflammatory protein-1. Int J Biochem Cell Biol 2004, 36:1882-1886.
63. Mor A., Aizman E., Kloog Y. Celecoxib enhances the anti-inflammatory effects of farnesylthiosalicylic acid on T cells independent of prostaglandin E(2) production. Inflammation 2012, 35:1706-1714.
64. Chizzolini C., Chicheportiche R., Alvarez M., de Rham C., Roux-Lombard P., Ferrari-Lacraz S., et al. Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood 2008, 112:3696-3703.
65. Fayette J., Soria J.C., Armand J.P. Use of angiogenesis inhibitors in tumour treatment. Eur J Cancer 2005, 41:1109-1116.
66. Toomey D.P., Murphy J.F., Conlon K.C. COX-2, VEGF and tumour angiogenesis. Surgeon 2009, 7:174-180.
67. Clarkin C.E., Emery R.J., Pitsillides A.A., Wheeler-Jones C.P. Evaluation of VEGF-mediated signaling in primary human cells reveals a paracrine action for VEGF in osteoblast-mediated crosstalk to endothelial cells. J Cell Physiol 2008, 214:537-544.
68. Moed B.R., Letournel E. Low-dose irradiation and indomethacin prevent heterotopic ossification after acetabular fracture surgery. J Bone Joint Surg Br 1994, 76:895-900.